Bleakley Financial Group LLC Has $141,000 Stock Holdings in Haleon plc (NYSE:HLN)

Bleakley Financial Group LLC grew its holdings in Haleon plc (NYSE:HLN) by 24.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,784 shares of the company’s stock after acquiring an additional 2,921 shares during the quarter. Bleakley Financial Group LLC’s holdings in Haleon were worth $141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Procyon Advisors LLC lifted its stake in shares of Haleon by 41.3% in the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock valued at $2,196,000 after buying an additional 67,329 shares during the period. HighTower Advisors LLC raised its stake in shares of Haleon by 27.2% in the 3rd quarter. HighTower Advisors LLC now owns 350,795 shares of the company’s stock valued at $3,701,000 after buying an additional 74,970 shares in the last quarter. Jane Street Group LLC increased its stake in Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after acquiring an additional 250,169 shares during the period. Chartwell Investment Partners LLC boosted its holdings in Haleon by 107.8% during the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock valued at $5,030,000 after purchasing an additional 246,594 shares in the last quarter. Finally, Townsquare Capital LLC lifted its position in shares of Haleon by 29.8% during the 3rd quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock worth $5,032,000 after buying an additional 109,217 shares during the period. Institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HLN shares. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

Shares of Haleon stock opened at $9.85 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The business has a 50-day moving average of $9.53 and a two-hundred day moving average of $9.79. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The company has a market capitalization of $44.59 billion, a P/E ratio of 28.97, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.